A high-throughout bioanalytical method based on a solid-phase extraction (SPE), and rapid liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis has been developed and validated for the quantification of mirtazapine (MRT) and desmethyl mirtazapine (DMRT) in heparinized human plasma. Plasma samples, without a drying and reconstitution step, were extracted by a simple SPE. The analytes and imipramine (internal standard, IS) chromatographed on a Betasil-C18 column. The total chromatographic run time was 1.8 min per sample. Response was a linear function of concentration in the range 0.1-100.0 ng/ml, with correlation coef-
ficient P0.9994. The assay has excellent characteristics and has been successfully applied to bioequivalence study samples for estimation of MRT and DMRT in healthy human subjects. ª 2010 King Saud University. Production and hosting by Elsevier B.V.
Introduction
Mirtazapine (MRT) is a tetracyclic piperazinoazepine, which has a different structure from any other currently used antidepressant. MRT is a potent antagonist of 5-HT 2 and 5-HT 3 receptors. MRT has no significant affinity for the 5-HT 1A and 5-HT 1B receptors. MRT is a potent antagonist of histamine (H 1 ) receptors, a property that may explain its prominent sedative effects. MRT is a moderate peripheral alpha1 adrenergic antagonist, a property that may explain the occasional orthostatic hypotension reported in association with its use. MRT is a moderate antagonist at muscarinic receptors, a property that may explain the relatively low incidence of anti-cholinergic side effects associated with its use. MRT is extensively metabolized after oral administration (Physicians Desk Reference (PDR), 2007; Baumann et al., 2006; SNaRIs et al., 2000) . Major pathways of biotransformation are demethylation and hydroxylation followed by glucuronide conjugation. In vitro data from human liver microsomes indicate that cytochrome 2D6 and 1A2 are involved in the formation of the 8-hydroxy metabolite of MRT, whereas cytochrome 3A is considered to be responsible for the formation of the N-desmethyl and Noxide metabolite. DMRT is the only pharmacologically active metabolite, which contributes only 3-6% to the total pharmacodynamic profile of MRT (Physicians Desk Reference (PDR), 2007, Baumann et al., 2006; SNaRIs et al., 2000) .
Several chromatographic methods including LC-UV (Dodd et al., 2000; de Santana et al., 2004; Romiguieres et al., 2002) , LC-DAD (Duverneuil et al., 2003; Titier et al., 2003) , LC-fluorescence detector (Maris et al., 1999; Ptaek et al., 2003) , CE detector (de Santana et al., 2008; Mandrioli et al., 2004) and LC-MS/MS (de Santana et al., 2008 (de Santana et al., , 2010 Wang et al., 2009; Pistos et al., 2004; Hong et al., 2008) have been developed to measure MRT and DMRT in biological fluids. LC-UV, LC-DAD, LC-fluorescence detector and CE methods are inadequate because of low sensitivity (LLOQ > 0.5 ng/ml), high injection volume (>5 ll), long chromatographic run time (>2.5 min) and large volume of plasma (>0.5 ml) required for analysis. Hence these methods allow determination of only 75-300 samples in a day, which is not enough for day to day analysis and commercial utilization in pharmacokinetics studies. Reported LC-MS/MS methods (de Santana et al., 2008 (de Santana et al., , 2010 Wang et al., 2009 ) are less sensitive having LLOQ 1.25, 62 and 10 ng/ml and chromatographic run time >2.4 min per sample. Another LC-MS/MS method (Pistos et al., 2004 ) is enough sensitive but requires run time >2.5 min, sample extraction involves laborious steps like evaporation and reconstitution. Although LC-MS/MS method reported for quantitation of MRT in human plasma by Hong et al., 2008 is sufficiently sensitive, this method requires laborious extraction procedure like LLE involving time-consuming and error-prone solvent evaporation and reconstitution steps and long run time.
This paper describes the development and validation of an LC-MS/MS method for the quantification of MRT and DMRT in human plasma, which reduces sample preparation and analysis time relative to other commonly employed techniques (LLE) and has a limit of quantitation (LOQ) 0.1 ng/ ml. Imipramine was used as an internal standard.
Experimental

Chemicals, reagents, standards
Pharmaceutical grade of MRT, DMRT and IS were kindly supplied by Vardha Biotech (Mumbai, Maharashtra, India) were certified to contain 99.45%, 99.65% and 96.90% respectively, and used without further purification. Organic solvents used where of gradient grade and were obtained from (Ranbaxy, Delhi, India). Water was obtained from a Milli-Q Gradient water purification system (Millipore, Bedford, Massachusetts, USA). Formic acid was of suprapur grade and obtained from Merck (Darmstadt, Germany). Ammonium formate used for mobile phase preparation was molecular biology-tested grade from Sigma-Aldrich (Steinheim, Germany). Oasis SPE cartridges were obtained from Waters (Massachusetts, Ireland). Control human plasma was obtained from Green Cross Laboratory and was stored below À70°C prior to use.
Stock solutions of MRT, DMRT and IS were prepared in methanol at free base concentration of 1 mg/ml, respectively. Secondary and working standard solutions were prepared from stock solutions by dilution with water. These diluted working standard solutions were used to prepare the calibration curve and quality control (QC) samples in human plasma.
A nine-point standard calibration curves for MRT and DMRT were prepared by spiking the blank plasma with appropriate amount of MRT and DMRT. The calibration curves were ranged from 0.1 to 100.0 ng/ml. Quality-control samples for MRT and DMRT were prepared in three concentration levels: 0.3 ng/ml LQC; 30 ng/ml MQC and 75 ng/ml HQC, in a manner similar to preparation of standard solutions from the stocks solution. 
Sample preparation
A 0.2 ml aliquot of human plasma (volunteers, CS and QC samples) was mixed with 25 ll of IS working solution (100 ng/ml of IS). The sample mixture was loaded into an Oasis HLB (1 cm 3 /30 mg), an extraction cartridge that was preconditioned with 1.0 ml methanol followed by 1.0 ml water. The extraction cartridge was washed with 2 ml water followed by 1.0 ml 10% methanol. MRT, DMRT and IS were eluted with 0.7 ml of acetonitrile; 3.0 ll of the eluate was injected into LC-MS/MS system.
LC-MS/MS
High-performance liquid chromatography was performed with a Prominence pump, autosampler, autoinjector, and column oven from Shimadzu (Kyoto, Japan). Mass spectrometry was performed with a TSQ Quantum triple-quadrupole mass spectrometer by Thermo Finnigan (Thermo Electron, San Jose, CA, USA). All LC and MS/MS conditions were controlled by LCquan software, version 2.5.6. Compounds were separated on a 100 mm · 3.0 mm, 3.0 lm particle, Betasil-C18 reversed-phase column (Thermo Electron Corporation). The column temperature was 45°C and the autosampler tray temperatures were 10°C. The mobile phase was (92:8, v/v) acetonitrile: 3 mM ammonium formate, pH adjusted to 3.5 with formic acid, at a flow rate of 0.5 ml/min. The chromatographic condition and mass spectrometric parameters are presented in Tables 1a and 1b ( Figs. 1-3) .
The LCquan software provided a standard method for calculations for quantitative analysis. Peak-area ratios of the calibrators were used in linear regression analysis with a weighting factor of 1/x 2 . The response curve was used to calculate the concentration of calibrators, QC, and stability samples. Initially, tuning of the MS conditions in both positive and negative modes was performed for MRT, DMRT and the IS, and the response was found to be much higher in positive-ionization mode. Use of Betasil-C18 (100 mm · 3.0 mm i.d., 3.0 lm) column enabled use of 0.5 ml/min flow rate, which resulted in run time as low as 1.8 min with better peak symmetry and signal of analytes. In several initial trials with ammonium formate and methanol for mobile phase optimization the response was low when pH of the ammonium formate was 3.5. The pKa values of MRT and DMRT are $7.1 but peak shape of analyte was not good. When 3 mM ammonium formate of pH 3.5 was used with acetonitrile good peak shape and improved signal were obtained with low background noise, resulting in higher specificity. The maximum backpressure during analysis was $48 bars. The optimum column oven temperature was 45°C, which resulted in symmetrical peaks.
In order to achieve cleanliness in extract, solid-phase extraction was optimized for extraction of analytes from plasma. Both the analytes and IS showed good retention when eluated with acetonitrile. In order to eliminate time-consuming and errorprone solvent evaporation and reconstitution steps for concentration of samples after elution with acetonitrile, the elution volume of acetonitrile was reduced to 0.7 ml to concentrate the sample in eluate. The optimized extraction condition enabled to reduce processing and analysis time. The sample injected 3.0 ll, avoided column backpressure and ESI source contamination during sample analysis in clinical studies.
Method validation
Selectivity and specificity
The specificity of the method was investigated by comparing chromatograms obtained from six different sources of plasma. The limit of detection (LOD) observed at 0.010 ng/ml concentration for both analytes. The SRM transitions 266.10 fi 195.10, 252.01 fi 180.00 and 281.07 fi 86.10 were chosen for quantification of MRT, DMRT and IS, respectively. The area observed at the retention time of MRT, DMRT was much less than 20% that of the LLOQ (ng/ml) area (Figs. 4 and 5).
Calibration curves
Five linearity curves containing nine non-zero concentrations were analyzed. The calibration curves were appeared linear and were well described by least squares lines. A weighting factor of 1/concentration i.e. 1/x 2 was chosen to achieve homogeneity of variance for MRT and DMRT. The accuracy and precision observed for the back calculated concentrations of five linearity from CS-1 to CS-9 are presented in Tables 2a and 2b. The correlation coefficient were P0.9994 (n = 5) for MRT and DMRT.
Sensitivity
The LLOQ is defined as the lowest concentration of the calibration standard yielding accuracy ±20% RE and precision of 620% RSD. The intra-run precision of LLOQ plasma samples containing MRT and DMRT were 3.85% and 7.44%, respectively. The mean intra-run accuracy of LLOQ plasma containing MRT and DMRT were 112.00% and 101.00%, respectively.
Recovery
Recovery of MRT and DMRT was calculated by comparing the peak area of the analyte from extracted plasma standard with that obtained from unextracted standard at the same concentration for quality-control samples containing 0.3, 30.0 and 75.0 ng/ml, respectively. The percent mean recovery for MRT and DMRT were observed 88.56 and 89.45, respectively. The mean recovery of IS was 92.50% at concentration 100.0 ng/ml.
Precision and accuracy
The intra-assay precision and accuracy were calculated in six replicates analyses for MRT and DMRT at four concentration level viz. LLOQ (0.10 ng/ml), LQC, (0.30 ng/ml), MQC, (30.0 ng/ml) and HQC, (75.0 ng/ml) each on the same analytical run. Inter-assay precision and accuracy was calculated after repeated analysis in three different analytical runs. The results are given in Tables 3 and 4 .
Matrix effect
Matrix effects were investigated for six different samples of plasma comprising four lots of normal control heparinzed plasma, one lot of lipemic plasma, and one lot of haemolyzed plasma. Three samples each at the LQC and HQC levels were prepared from different lots of plasma (i.e. a total of 36 QC samples) and checked for accuracy, to see whether the matrix affected the back-calculated value of the nominal concentrations for these different plasma samples. The results obtained were well within the acceptable limit of ±15%, which clearly proves that elution of endogenous matrix peaks in the dead volume time does not affect the pattern of elution of MRT, DMRT and IS, respectively.
Stability
Exhaustive experiments were performed to assess the stability of MRT, DMRT in stock solution and in plasma samples under different conditions simulating the conditions occurring during analysis of study samples--room-temperature stability, extracted sample stability (process stability), freeze-thaw stability, and long-term stability of plasma samples. The results obtained were well within acceptable limits. IS stock solution was also found to be stable. Stock solutions of MRT, DMRT and IS were stable at room temperature for 20 h and at 2-8°C for 28 days. MRT and DMRT in control human plasma were stable for 12.0 h at room temperature. Both the analytes in extracted plasma samples were stable for 58 h in an autosampler at 10°C. MRT and DMRT were found stable at least four freeze-thaw cycles. MRT and DMRT spiked plasma samples stored at À70°C to test long-term stability were stable for at least 68 days. Percentage changes of concentration in these stability experiments are listed in Tables 5 and 6. 
Application of method
The proposed validated method was successfully applied for the assay of MRT and DMRT in 18 healthy adult male human subject samples who received 30 mg of mirtazapine tablet under fasting condition. A total of 1120 plasma samples from (Fig. 6 ). Thus the assay procedure for MRT and DMRT in plasma samples demonstrated the linearity, precision and sensitivity needed for the pharmacokinetic studies of this drug. The mean plasma concentration of MRT and DMRT are shown in Fig. 7 .
Conclusion
The objective of this work was to develop a simple, specific, rugged and a high throughput method for simultaneous estimation of MRT and its active metabolites DMRT in human plasma. The advantage of using an SPE technique in the present work is due to: (i) minimize the sample extraction time, (ii) present method has been used only 200 ll of human plasma compare to reported methods and hence to reduce the amount of blood withdrawn from volunteers during study, (iii) significant reduction in the labor commonly associated with LLE technique on account of flash freezing of aqueous part, (iv) because of rapid sample preparation technology and short chromatographic run time, large numbers of pharmacokinetic samples can be analyzed. Moreover, the limit of quantification is low enough to monitor at least five half life of MRT and DMRT with good intra and inter-assay reproducibility (%CV) for the quality control. From the results of validation parameters, the method can be useful for therapeutic drug monitoring both for analysis of routine samples of a single dose or multiple dose pharmacokinetic and also for the clinical trial samples with desired precision and accuracy.
Figure 7
Mean plasma concentration and time profile for mirtazapine and desmethyl mirtazapine.
